Effects of oral and transdermal estrogen on IGF1, IGFBP3, IGFBP1, serum lipids, and glucose in patients with hypopituitarism during GH treatment: a randomized study
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Objective: To evaluate the effects of oral estradiol and transdermal 17β-estradiol on serum concentrations of IGF1 and its binding proteins in women with hypopituitarism. Design: Prospective, comparative study. Methods: Eleven patients with hypopituitarism were randomly allocated to receive 2 mg oral estradiol (n=6) or 50 μg/day of transdermal 17β-estradiol (n=5) for 3 months. Results: The oral estrogen group showed a significant reduction in IGF1 levels (mean: 42.7%±41.4,P=0.046); no difference was observed in the transdermal estrogen group. There was a significant increase in IGFBP1 levels (mean: 170.2%±230.9,P=0.028) in the oral group, but not in the transdermal group. There was no significant difference within either group in terms of median IGFBP3 levels. In relation to lipid profiles, there was a significant increase in mean high-density lipoprotein cholesterol levels in the oral group after 3 months of treatment, (27.8±9.3,P=0.003). We found no differences in the anthropometric measurements, blood pressure, heart rate, glucose, insulin, C-peptide, or the homeostasis model assessment index after treatment. Conclusions: Our preliminary data indicate that different estrogen administration routes can influence IGF1 and IGFBP1 levels. These findings in patients with hypopituitarism have an impact on their response to treatment with GH, since patients receiving oral estrogen require increased GH dosage. These results suggest that oral estrogens may reduce the beneficial effects of GH replacement on fat and protein metabolism, body composition, and quality of life.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WEISSBERGER, A. J., HO, K. K. Y., & LAZARUS, L. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-72-2-374 · Cited by 514
Sandhu, M. S., Heald, A. H., Gibson, J. M., Cruickshank, J. K., Dunger, D. B., & Wareham, N. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08655-5 · Cited by 470
Dr. Ho, K. K. Y., & Weissberger, A. J. (1992) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650070711 · Cited by 91
Gibney, J., Johannsson, G., Leung, K.-C., & Ho, K. K. Y. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0173 · Cited by 40
Cited by
Sex steroids and the GH axis: implications for the management of hypopituitarism
Birzniece, V., & Ho, K. K. Y. (2017) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2017.03.003 · Cited by 65
Increase of circulating IGFBP-4 following genotoxic stress and its implication for senescence
Alessio, N., Squillaro, T., Di Bernardo, G., Galano, G., De Rosa, R., Melone, M. A., Peluso, G., & Galderisi, U. (2020) · eLife · doi:10.7554/elife.54523 · Cited by 51
“We selected only male patients to reduce variability, since there are findings showing that IGF-associated pathways can be influenced by estrogen fluctuation (Isotton et al., 2012).”
BackgroundCleemann, L., Holm, K., Kobbernagel, H., Kristensen, B., Skouby, S. O., Jensen, A. K., & Gravholt, C. H. (2017) · European Journal of Endocrinology · doi:10.1530/eje-16-0582 · Cited by 48
Metadata
- Authors
- Isotton, A. L., Wender, M. C. O., Casagrande, A., Rollin, G., & Czepielewski, M. A.
- Venue
- European Journal of Endocrinology
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-02
- Volume
- 166
- Issue
- 2
- Pages
- 207-213
- ISSN
- 0804-4643 (ISSN-L)
- 1479-683X
- OpenAlex
- W2155800968
- Cited by
- 49
- References
- 4
- FWCI
- 1.41
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of oral and transdermal estrogen on IGF1, IGFBP3, IGFBP1, serum lipids, and glucose in patients with hypopituitarism during GH treatment: a randomized study. https://app.cochat.ai/papers/10.1530/eje-11-0560
- The paper
- Isotton, A. L., Wender, M. C. O., Casagrande, A., Rollin, G., & Czepielewski, M. A. (2012). Effects of oral and transdermal estrogen on IGF1, IGFBP3, IGFBP1, serum lipids, and glucose in patients with hypopituitarism during GH treatment: a randomized study. European Journal of Endocrinology. https://doi.org/10.1530/eje-11-0560
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.